Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

M. Alexander, M. L. Salgaller, Esteban Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, M. A. Steller

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

OBJECTIVE: Approximately 90% of squamous carcinomas of the cervix harbor the human papillomavirus and type 16 has been detected in nearly 50% of cases. Recent studies in mice have shown that the human papillomavirus type 16 E7 oncoprotein contains peptide epitopes that are processed and presented in association with a major histocompatibility antigen for recognition by cytolytic T lymphocytes. We investigated whether an epitope from human papillomavirus type 16 E7 could be used to generate specific human cytolytic T lymphocytes in patients with cervical carcinoma. STUDY DESIGN: After radiation therapy, three patients with antigen HLA-A2 and with locally advanced cervical cancer underwent leukapheresis. Epitope-specific cytolytic T lymphocytes were generated from the peripheral blood mononuclear cells by in vitro stimulation with autologous peripheral blood mononuclear cells pulsed with a human papillomavirus type 16 E7, HLA-A2-restricted, synthetic peptide, E711-20 (YMLDLQPETT). RESULTS: In two patients cytolytic T lymphocytes were capable of E7711-20-specific, HLA-A2-restricted cytolysis of the peptide-pulsed, HLA-matched, T2 target cell line. Cytolytic T lymphocytes from one of these patients also demonstrated specific cytolysis against the HLA-A2+, HPV-16+ CaSki cervical cancer cell line but did not lyse either HLA-A2+, HPV-16 MS-751 cells or HLA-A2+, HPV-16 HT-3 cells. CONCLUSIONS: These experiments demonstrate that novel cytolytic T lymphocytes that recognize a human papillomavirus type 16 E7 epitope can be generated by using the peripheral blood mononuclear cells from irradiated patients with cervical cancer. In addition, because CaSki cells were specifically lysed by the cytolytic T lymphocytes, these data indicate that the peptide E7711- 20 is endogenously processed and presented on the cell surface of the CaSki cells. The demonstration of epitope-specific lysis of cytolytic T lymphocytes of HPV-16+ cervical cancer cells supports further efforts to develop human papillomavirus peptide-based vaccines or antigen-specific adoptive immunotherapy for the prevention and treatment of cervical carcinoma.

Original languageEnglish (US)
Pages (from-to)1586-1593
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume175
Issue number6
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Human papillomavirus 16
Uterine Cervical Neoplasms
HLA-A2 Antigen
Epitopes
T-Lymphocytes
Neoplasms
Blood Cells
Peptides
Leukapheresis
Carcinoma
Adoptive Immunotherapy
In Vitro Techniques
Papillomavirus Vaccines
Cell Line
Subunit Vaccines
Histocompatibility Antigens
Oncogene Proteins
Cervix Uteri
Squamous Cell Carcinoma
Radiotherapy

Keywords

  • Human papillomavirus
  • cervical cancer
  • cytolytic T lymphocytes
  • peptide epitopes
  • vaccine

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. / Alexander, M.; Salgaller, M. L.; Celis, Esteban; Sette, A.; Barnes, W. A.; Rosenberg, S. A.; Steller, M. A.

In: American Journal of Obstetrics and Gynecology, Vol. 175, No. 6, 01.01.1996, p. 1586-1593.

Research output: Contribution to journalArticle

@article{a51a9b759df1438daa6137916db5519b,
title = "Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope",
abstract = "OBJECTIVE: Approximately 90{\%} of squamous carcinomas of the cervix harbor the human papillomavirus and type 16 has been detected in nearly 50{\%} of cases. Recent studies in mice have shown that the human papillomavirus type 16 E7 oncoprotein contains peptide epitopes that are processed and presented in association with a major histocompatibility antigen for recognition by cytolytic T lymphocytes. We investigated whether an epitope from human papillomavirus type 16 E7 could be used to generate specific human cytolytic T lymphocytes in patients with cervical carcinoma. STUDY DESIGN: After radiation therapy, three patients with antigen HLA-A2 and with locally advanced cervical cancer underwent leukapheresis. Epitope-specific cytolytic T lymphocytes were generated from the peripheral blood mononuclear cells by in vitro stimulation with autologous peripheral blood mononuclear cells pulsed with a human papillomavirus type 16 E7, HLA-A2-restricted, synthetic peptide, E711-20 (YMLDLQPETT). RESULTS: In two patients cytolytic T lymphocytes were capable of E7711-20-specific, HLA-A2-restricted cytolysis of the peptide-pulsed, HLA-matched, T2 target cell line. Cytolytic T lymphocytes from one of these patients also demonstrated specific cytolysis against the HLA-A2+, HPV-16+ CaSki cervical cancer cell line but did not lyse either HLA-A2+, HPV-16 MS-751 cells or HLA-A2+, HPV-16 HT-3 cells. CONCLUSIONS: These experiments demonstrate that novel cytolytic T lymphocytes that recognize a human papillomavirus type 16 E7 epitope can be generated by using the peripheral blood mononuclear cells from irradiated patients with cervical cancer. In addition, because CaSki cells were specifically lysed by the cytolytic T lymphocytes, these data indicate that the peptide E7711- 20 is endogenously processed and presented on the cell surface of the CaSki cells. The demonstration of epitope-specific lysis of cytolytic T lymphocytes of HPV-16+ cervical cancer cells supports further efforts to develop human papillomavirus peptide-based vaccines or antigen-specific adoptive immunotherapy for the prevention and treatment of cervical carcinoma.",
keywords = "Human papillomavirus, cervical cancer, cytolytic T lymphocytes, peptide epitopes, vaccine",
author = "M. Alexander and Salgaller, {M. L.} and Esteban Celis and A. Sette and Barnes, {W. A.} and Rosenberg, {S. A.} and Steller, {M. A.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(96)70110-2",
language = "English (US)",
volume = "175",
pages = "1586--1593",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

AU - Alexander, M.

AU - Salgaller, M. L.

AU - Celis, Esteban

AU - Sette, A.

AU - Barnes, W. A.

AU - Rosenberg, S. A.

AU - Steller, M. A.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - OBJECTIVE: Approximately 90% of squamous carcinomas of the cervix harbor the human papillomavirus and type 16 has been detected in nearly 50% of cases. Recent studies in mice have shown that the human papillomavirus type 16 E7 oncoprotein contains peptide epitopes that are processed and presented in association with a major histocompatibility antigen for recognition by cytolytic T lymphocytes. We investigated whether an epitope from human papillomavirus type 16 E7 could be used to generate specific human cytolytic T lymphocytes in patients with cervical carcinoma. STUDY DESIGN: After radiation therapy, three patients with antigen HLA-A2 and with locally advanced cervical cancer underwent leukapheresis. Epitope-specific cytolytic T lymphocytes were generated from the peripheral blood mononuclear cells by in vitro stimulation with autologous peripheral blood mononuclear cells pulsed with a human papillomavirus type 16 E7, HLA-A2-restricted, synthetic peptide, E711-20 (YMLDLQPETT). RESULTS: In two patients cytolytic T lymphocytes were capable of E7711-20-specific, HLA-A2-restricted cytolysis of the peptide-pulsed, HLA-matched, T2 target cell line. Cytolytic T lymphocytes from one of these patients also demonstrated specific cytolysis against the HLA-A2+, HPV-16+ CaSki cervical cancer cell line but did not lyse either HLA-A2+, HPV-16 MS-751 cells or HLA-A2+, HPV-16 HT-3 cells. CONCLUSIONS: These experiments demonstrate that novel cytolytic T lymphocytes that recognize a human papillomavirus type 16 E7 epitope can be generated by using the peripheral blood mononuclear cells from irradiated patients with cervical cancer. In addition, because CaSki cells were specifically lysed by the cytolytic T lymphocytes, these data indicate that the peptide E7711- 20 is endogenously processed and presented on the cell surface of the CaSki cells. The demonstration of epitope-specific lysis of cytolytic T lymphocytes of HPV-16+ cervical cancer cells supports further efforts to develop human papillomavirus peptide-based vaccines or antigen-specific adoptive immunotherapy for the prevention and treatment of cervical carcinoma.

AB - OBJECTIVE: Approximately 90% of squamous carcinomas of the cervix harbor the human papillomavirus and type 16 has been detected in nearly 50% of cases. Recent studies in mice have shown that the human papillomavirus type 16 E7 oncoprotein contains peptide epitopes that are processed and presented in association with a major histocompatibility antigen for recognition by cytolytic T lymphocytes. We investigated whether an epitope from human papillomavirus type 16 E7 could be used to generate specific human cytolytic T lymphocytes in patients with cervical carcinoma. STUDY DESIGN: After radiation therapy, three patients with antigen HLA-A2 and with locally advanced cervical cancer underwent leukapheresis. Epitope-specific cytolytic T lymphocytes were generated from the peripheral blood mononuclear cells by in vitro stimulation with autologous peripheral blood mononuclear cells pulsed with a human papillomavirus type 16 E7, HLA-A2-restricted, synthetic peptide, E711-20 (YMLDLQPETT). RESULTS: In two patients cytolytic T lymphocytes were capable of E7711-20-specific, HLA-A2-restricted cytolysis of the peptide-pulsed, HLA-matched, T2 target cell line. Cytolytic T lymphocytes from one of these patients also demonstrated specific cytolysis against the HLA-A2+, HPV-16+ CaSki cervical cancer cell line but did not lyse either HLA-A2+, HPV-16 MS-751 cells or HLA-A2+, HPV-16 HT-3 cells. CONCLUSIONS: These experiments demonstrate that novel cytolytic T lymphocytes that recognize a human papillomavirus type 16 E7 epitope can be generated by using the peripheral blood mononuclear cells from irradiated patients with cervical cancer. In addition, because CaSki cells were specifically lysed by the cytolytic T lymphocytes, these data indicate that the peptide E7711- 20 is endogenously processed and presented on the cell surface of the CaSki cells. The demonstration of epitope-specific lysis of cytolytic T lymphocytes of HPV-16+ cervical cancer cells supports further efforts to develop human papillomavirus peptide-based vaccines or antigen-specific adoptive immunotherapy for the prevention and treatment of cervical carcinoma.

KW - Human papillomavirus

KW - cervical cancer

KW - cytolytic T lymphocytes

KW - peptide epitopes

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=0030466136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030466136&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(96)70110-2

DO - 10.1016/S0002-9378(96)70110-2

M3 - Article

VL - 175

SP - 1586

EP - 1593

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -